1-4 of 4
cost-benefit analysis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Cost-Benefit Analysis of Bortezomib, Lenalidomide, and Bortezomib/Lenalidomide Combination Therapy for Newly Diagnosed Multiple Myeloma

Mark A. Fiala, BS, Tanya M. Wildes, MDMSCI, Gunjan L. Shah, MD, Armin Ghobadi, MD, Mark A. Schroeder, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MDMBA
Journal: Blood
Blood (2017) 130 (Supplement 1): 3108.
https://doi.org/10.1182/blood.V130.Suppl_1.3108.3108
Published: 2017
Journal Articles

Cost Benefit Analysis Of a Sickle Cell Infusion Center For The Treatment Of Vaso-Occlusive Crises

Meera Chappidi, Y. Natalia Alfonso, MA, David Bishai, MD, PhD, MPH, Sophie Lanzkron, MD, MHS
Journal: Blood
Blood (2013) 122 (21): 1697.
https://doi.org/10.1182/blood.V122.21.1697.1697
Published: 2013
Journal Articles

Cost-Benefit Analysis of Primary Prophylaxis with Granulocyte Colony Stimulating Factor (GCSF) in Reducing Hospital Admissions with Febrile Neutropenia in Patients Undergoing High Dose Chemotherapy for Non-Hodgkin Lymphoma (NHL).

Sophie Lee, MD, Hilary Blacklock, MD, Samar Issa, MD
Journal: Blood
Blood (2009) 114 (22): 4764.
https://doi.org/10.1182/blood.V114.22.4764.4764
Published: 2009
Journal Articles

A Cost-Benefit Analysis of D-Dimer Measurement by a High Sensitivity Asay, as the First Step to Rule out a Venous Thromboembolism Suspected Episode, Independently of Pretest Clinical Probability.

Francesc J Casals, MD, PhD, Davide Bernaudo, MD, Jaume Villalta, MD, Naila Lozano, RN, Gines Escolar, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1280.
https://doi.org/10.1182/blood.V112.11.1280.1280
Published: 2008